Reata Pharma (RETA) Tops Q2 EPS by 8c

Reata Pharma (NASDAQ: RETA) reported Q2 EPS of ($2.00), $0.08 better than the analyst estimate of ($2.08). Revenue for the quarter came in at $2.2 million versus the consensus estimate of $1.25 million.

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• INVO Fertility (IVF) Tops Q2 EPS by 105c